



Development of Vaccines against Tuberculosis: One Health Approach

Guest Editor:

Dr. Bernat Pérez de Val

Institute of Agrifood Research
and Technology—Research
Center for Animal Health (IRTA-
CReSA), 08193 Bellaterra,
Barcelona, Spain

Deadline for manuscript
submissions:

closed (30 November 2021)

Message from the Guest Editor

This Special Issue focuses on recent research and development of vaccines against human and animal TB. We particularly encourage you to contribute with an original article or review to highlight (i) recent advances in novel prophylactic and post-exposure TB vaccines; (ii) animal models, delivery modalities, immune responses to vaccination, and correlates of protection; (iii) development of vaccination-compatible diagnoses (DIVA); and (iv) field trials.

Keywords:

- tuberculosis
- one health
- zoonosis
- vaccines
- animal models
- efficacy
- safety
- immune responses
- BCG
- DIVA

Dr. Bernat Pérez de Val

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ger Rijkers

Department of Health, Cognition
and Behavior, University College
Roosevelt, 4331 CB Middelburg,
The Netherlands

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X), founded in 2013, now has a firm history of publishing peer-reviewed, state-of-the-art research papers on vaccines and vaccination in the broadest sense. Areas covered include, but are not limited to, novel and emerging vaccine technologies, building on in-depth knowledge of what constitutes a protective immune response. These can be new vaccines for old diseases, or old vaccines for new diseases. Vaccines against cancer and autoimmune diseases explicitly are also within the scope of the journal. Because public opinion and even government policies towards vaccines and vaccination have changed, vaccine policy and public health issues are major concerns. Climate change will also have an impact on the spread of infectious diseases, and thus also on vaccine and vaccination policies worldwide.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.**

Journal Rank: JCR - Q2 (Medicine, Research and Experimental) / CiteScore - Q1 (Pharmacology (medical))

Contact Us

Vaccines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com
[X@Vaccines_MDPI](https://twitter.com/Vaccines_MDPI)